These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 18555911)

  • 1. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial.
    Wood DA; Kotseva K; Connolly S; Jennings C; Mead A; Jones J; Holden A; De Bacquer D; Collier T; De Backer G; Faergeman O;
    Lancet; 2008 Jun; 371(9629):1999-2012. PubMed ID: 18555911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risk reduction: impact of an international project].
    Colle B; Brusaferro S;
    Ann Ig; 2008; 20(3 Suppl 1):43-8. PubMed ID: 18773604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nurse-led and Interdisciplinary Secondary Cardiovascular Prevention Programmes: Spanish Cohort of the EUROACTION Project.
    Buigues C; Trapero I; Velasco JA; Salvador-Sanz A; Jennings C; Wood D; Queralt A
    Endocr Metab Immune Disord Drug Targets; 2022; 22(13):1319-1329. PubMed ID: 35362378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial.
    Jennings C; Kotseva K; De Bacquer D; Hoes A; de Velasco J; Brusaferro S; Mead A; Jones J; Tonstad S; Wood D;
    Eur Heart J; 2014 Jun; 35(21):1411-20. PubMed ID: 24616337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk.
    Woollard J; Burke V; Beilin LJ; Verheijden M; Bulsara MK
    J Cardiovasc Risk; 2003 Feb; 10(1):31-40. PubMed ID: 12569235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain.
    Buigues C; Queralt A; De Velasco JA; Salvador-Sanz A; Jennings C; Wood D; Trapero I
    Endocr Metab Immune Disord Drug Targets; 2020; 20(9):1412-1418. PubMed ID: 32520696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of evidence-based guidelines in preventive cardiology: the EUROACTION program.
    Pearson TA;
    Nat Clin Pract Cardiovasc Med; 2009 Jan; 6(1):8-9. PubMed ID: 18941437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease.
    Vale MJ; Jelinek MV; Best JD; Dart AM; Grigg LE; Hare DL; Ho BP; Newman RW; McNeil JJ;
    Arch Intern Med; 2003 Dec 8-22; 163(22):2775-83. PubMed ID: 14662633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
    Hradec J; Zamorano J; Sutradhar S
    Curr Med Res Opin; 2013 Jun; 29(6):589-96. PubMed ID: 23464930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease.
    Vestfold Heartcare Study Group
    Eur J Cardiovasc Prev Rehabil; 2003 Dec; 10(6):429-37. PubMed ID: 14671465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.
    Xavier D; Gupta R; Kamath D; Sigamani A; Devereaux PJ; George N; Joshi R; Pogue J; Pais P; Yusuf S
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):244-253. PubMed ID: 26857999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group.
    BMJ; 1994 Jan; 308(6924):313-20. PubMed ID: 8124121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland.
    Gibson I; Flaherty G; Cormican S; Jones J; Kerins C; Walsh AM; Costello C; Windle J; Connolly S; Crowley J
    Eur J Prev Cardiol; 2014 Mar; 21(3):366-76. PubMed ID: 23884981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment.
    Mohammed MA; El Sayed C; Marshall T
    Med Decis Making; 2012; 32(3):498-506. PubMed ID: 22357626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Lancet; 2009 Mar; 373(9667):929-40. PubMed ID: 19286092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):121-37. PubMed ID: 19287307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.